Method, kit, and apparatus for cancer detection using urinary tumor markers
a cancer and urine technology, applied in the field of neuroblastoma detection methods, kits and apparatuses, can solve the problems of excessive examination and therapy, and the inability of examination to effectively reduce mortality, and achieve the effect of convenient and inexpensive detection of neuroblastoma, good prognosis, and simplified collection or sampling techniqu
Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- Publication Date
- 2020-05-14
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
RELATED APPLICATION
[0001] This application claims the benefit of priority to Japanese Patent Application number 2018-212341, filed Nov. 12, 2018, hereby incorporated by reference in its entirety.TECHNICAL FIELD
[0002] The present invention relates to methods, kits, and apparatuses for detecting a neuroblastoma in a subject using urinary tumor markers derived from the subject.BACKGROUND ART
[0003] Neuroblastoma is one of childhood cancers and is often diagnosed at 0 to 4 years of age. Neuroblastoma tumor cells produce catecholamine, which is a neurotransmitter, and the catecholamine converts into vanillylmandelic acid (VMA) and homovanillic acid (HVA), and they are excreted into the urine. Neuroblastoma mass screening examination that detects or determines VMA and HVA has been performed on six-month-old infants as subjects, to detect neuroblastoma early. Unfortunately, questions remain as to the efficacy of the examination (for example, Japanese Unexamined Patent Application Publication N...
Examples
example 1
sive Analysis of Neuroblastoma-Related Urinary Metabolites
[0151]To identify urinary tumor markers specific to neuroblastoma, a global analysis of urinary metabolites was performed on 58 healthy children and 7 neuroblastoma-affected children before therapy, in Nagoya University Graduate School of Medicine, Surgery, Pediatric Surgery Laboratory.
[0152]Specifically, metabolites in urine of neuroblastoma-affected children and in urine of healthy children of the same age were comprehensively analyzed using a liquid chromatograph-mass spectrometer (LC / MS) to specify metabolites that significantly increase or decrease in the childhood cancer-affected (neuroblastoma-affected) children as compared with the healthy children, to thereby find urinary tumor markers that can distinguish between healthy children and childhood cancer-affected children by multivariate analysis. As a result, urinary tumor markers that distinguish between the two groups were found (Japanese Patent Application No. 2018-...
example 2
ion of Cancer Evaluation Model Using Group (A) Markers and Group (B) Markers
[0158]On each of the Group (A) markers and the Group (B) markers selected in Example 1, prediction models were made by OPLS-DA on all combinations, and the performance indices (in particular, predictor variables) of the models were determined. In particular, combinations of urinary metabolites involved in different metabolisms were selected as marker candidates.
[0159]Specifically, to distinguish between healthy children and neuroblastoma-affected children, cancer examination models were determined by orthogonal projections to latent structures-discriminant analysis (OPLS-DA) using indices expressed as follows:
R2Y=1-Σ(Yobs-Ycalc)2Σ(Yobs-Y_)2Q2=1-Σ(Yobs-Ypred)2Σ(Yobs-Y_)2
[0160]In the expressions, Yobs represents the measured value; Ycalc represents the value calculated by OPLS; Ypred represents the predicted value according to cross-validation; and represents the average. The “cross-validation” refers to a tec...